Truist Securities Maintains Buy on Gilead Sciences, Lowers Price Target to $156

Benzinga Newsdesk www.benzinga.com Negative 47.7%

Neg 47.7% Neu 0% Pos 0%

Truist Securities analyst Gregory Renza maintains Gilead Sciences (NASDAQ:GILD) with a Buy and lowers the price target from $157 to $156.